Literature DB >> 10747835

Clinical relevance of Proteus mirabilis in hospital patients: a two year survey.

C de Champs1, R Bonnet, D Sirot, C Chanal, J Sirot.   

Abstract

A retrospective study was performed on 1072 non-duplicate isolates of Proteus mirabilis, taken in the period April 1996 to March 1998, and on 100 patient charts randomly selected during the same period. P. mirabilis isolates accounted for 7.7% of Enterobacteriaceae. The isolates were predominantly from urine (70.2%); of the total, 38.0% were penicillinase-producing isolates, 6.9% were extended-spectrum beta-lactamase (ESBL)-producing isolates and 3.6% produced inhibitor-resistant beta-lactamase (IRB). ESBL-producing isolates were observed in long-stay and intensive care and IRB-producing isolates in paediatric units. Of the 95 patients whose charts were examined, 69 had a confirmed infection, which in 42 cases was nosocomial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747835     DOI: 10.1093/jac/45.4.537

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.

Authors:  C de Champs; C Monne; R Bonnet; W Sougakoff; D Sirot; C Chanal; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes.

Authors:  K Cohen-Nahum; L Saidel-Odes; K Riesenberg; F Schlaeffer; A Borer
Journal:  Infection       Date:  2009-12-07       Impact factor: 3.553

4.  Neonatal meningoventriculitis due to proteus mirabilis - a case report.

Authors:  Deepak Juyal; Vyas Kumar Rathaur; Neelam Sharma
Journal:  J Clin Diagn Res       Date:  2012-12-24

5.  Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital.

Authors:  C Chanal; R Bonnet; C De Champs; D Sirot; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  An assessment of fecal indicator and other bacteria from an urbanized coastal lagoon in the City of Los Angeles, California, USA.

Authors:  John H Dorsey; Víctor D Carmona-Galindo; Christopher Leary; Julie Huh; Jennifer Valdez
Journal:  Environ Monit Assess       Date:  2012-07-06       Impact factor: 2.513

7.  Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey.

Authors:  Francesco Luzzaro; Marilina Mezzatesta; Claudia Mugnaioli; Mariagrazia Perilli; Stefania Stefani; Gianfranco Amicosante; Gian Maria Rossolini; Antonio Toniolo
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

8.  DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.

Authors:  L M Weigel; G J Anderson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type beta-lactamase.

Authors:  Noriyuki Nagano; Naohiro Shibata; Yuko Saitou; Yukiko Nagano; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  Integration of a transposon Tn1-encoded inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome.

Authors:  Thierry Naas; Marie Zerbib; Delphine Girlich; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.